Document is current
Any future updates will be listed below
-
Authors
Lantsman, Taliya
Matulonis, Ursula A.
- License Information
-
More Information
Article History
Accepted: 3 November 2025
First Online: 17 February 2026
Declarations
:
: Taliya Lantsman declares no conflicts of interest that might be relevant to the contents of this article. Ursula A. Matulonis reports participation in scientific advisory boards (Allarity, NextCure, AbbVie, Immunogen, Profound Bio, Eisai, the Ovarian Cancer Research Alliance, Tango Therapeutics, Novartis, GSK, Daiichi Sankyo, DayOne Bio, and Whitehawk Therapeutics), participation in a data safety-monitoring board (Mural Oncology, Macrogenics, and Symphogen), and consulting (Merck).
: Not applicable (N/A).
: N/A.
: N/A.
: No datasets were generated or analyzed during the current study.
: N/A.
: Taliya Lantsman and Ursula A. Matulonis contributed in the drafting and editing of the manuscript.
